{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma+%28mCRC%29&page=2", "query": { "condition": "Metastatic Colorectal Carcinoma (mCRC)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Colorectal+Carcinoma+%28mCRC%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T05:08:34.152Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01478594", "title": "A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Tivozanib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 265, "start_date": "2011-12", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2015-07-08", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 27, "location_summary": "Gilbert, Arizona • Hot Springs, Arizona • Tucson, Arizona + 22 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478594" }, { "nct_id": "NCT00594984", "title": "Phase I/II Combination With Irinotecan- Erbitux", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer (MCRC)" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Brivanib", "type": "DRUG" }, { "name": "Brivanib Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2008-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 4, "location_summary": "Los Angeles, California • Louisville, Kentucky • St Louis, Missouri", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594984" }, { "nct_id": "NCT01490866", "title": "A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2012-01", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2019-09-24", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 12, "location_summary": "Jonesboro, Arkansas • Fort Myers, Florida • Pensacola, Florida + 9 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Gainesville", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490866" }, { "nct_id": "NCT07463599", "title": "Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Carcinoma (mCRC)", "Colorectal Cancer (CRC)", "Adenomatous Polyposis Coli (APC) Gene Mutation", "Catenin Beta-1 (CTNNB1) Gene Mutation" ], "interventions": [ { "name": "Tegavivint", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HonorHealth Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2026-02-17", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07463599" }, { "nct_id": "NCT07011576", "title": "A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Rectal Cancer", "Colorectal Cancer", "Colorectal Cancer (CRC)" ], "interventions": [ { "name": "fruquintinib", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-09-29", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 14, "location_summary": "Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Arlington Heights", "state": "Illinois" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Maple Grove", "state": "Minnesota" }, { "city": "Columbia", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07011576" }, { "nct_id": "NCT00561470", "title": "Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)", "type": "DRUG" }, { "name": "FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1226, "start_date": "2007-11", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2012-09-28", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Hot Springs, Arizona + 68 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561470" }, { "nct_id": "NCT01598597", "title": "An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Non-Small Cell Lung Cancer", "Glioblastoma", "Renal Cell Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2012-03", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2015-05-08", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 50, "location_summary": "Many Locations, Alabama • Many Locations, Alaska • Many Locations, Arizona + 47 more", "locations": [ { "city": "Many Locations", "state": "Alabama" }, { "city": "Many Locations", "state": "Alaska" }, { "city": "Many Locations", "state": "Arizona" }, { "city": "Many Locations", "state": "Arkansas" }, { "city": "Many Locations", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01598597" }, { "nct_id": "NCT03365882", "title": "S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Adenocarcinoma", "ERBB2 Gene Amplification", "Rectal Adenocarcinoma", "Recurrent Colon Carcinoma", "Recurrent Rectal Carcinoma", "Stage III Colon Cancer AJCC v7", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Colon Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Colon Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Colon Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Colon Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Colon Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Colon Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "HER-2 testing", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "DEVICE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2017-11-27", "completion_date": "2025-07-01", "has_results": true, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 786, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03365882" }, { "nct_id": "NCT04166383", "title": "VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Colorectal Cancer With Hepatic Metastases", "Colorectal Tumors" ], "interventions": [ { "name": "Vascular Biogenics (VB)-111", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-08-09", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2026-03-10", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166383" }, { "nct_id": "NCT00819780", "title": "PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer", "Colorectal Cancer", "Rectal Cancer", "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2009-04-24", "completion_date": "2016-07-07", "has_results": true, "last_update_posted_date": "2022-12-06", "last_synced_at": "2026-05-22T05:08:34.152Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Berkeley, California + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00819780" } ] }